Air classifier technology (ACT) in dry powder inhalation: Part 3. Design and development of an air classifier family for the Novolizer® multi-dose dry powder inhaler

International Journal of Pharmaceutics

Volumn 310, Issue 1-2, 2006, Pages 72-80

  De Boer, A H ^a   Hagedoorn, P ^a   Gjaltema, D ^a   Goede, J ^b   Frijlink, H W ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b VIATRIS GmbH and Co KG   (Germany)

Author keywords

Adhesive mixtures; Air classifier technology; Carrier lactose; Dry powder inhalation; Novolizer ; Spherical pellets

Indexed keywords

BUDESONIDE; DRUG CARRIER;

AEROSOL; AIRFLOW; ARTICLE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG TRANSPORT; DRY POWDER; FLOW RATE; INHALATION; INHALER; PRIORITY JOURNAL;

ADHESIVENESS; ADMINISTRATION, INHALATION; AEROSOLS; BRONCHODILATOR AGENTS; BUDESONIDE; CHEMISTRY, PHARMACEUTICAL; DRUG CARRIERS; EQUIPMENT DESIGN; LACTOSE; NEBULIZERS AND VAPORIZERS; PARTICLE SIZE; POWDERS; TIME FACTORS;

EID: 33344470868     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2005.11.030     Document Type: Article

References (43)

1. Amass, J.M., 1996. A study of drug carrier interactions in dry powder inhalers. Thesis. Dept. of Biol. & Chem. Sci., University of Essex, UK, pp. 170-189.
2. P.B. Anderson, and N.C.G. Hansen Which magnitude of inhaler resistance against airflow is preferred by patients using dry powder devices? Eur. Respir. J. 6 1993 148S
3. I. Ashurst, A. Malton, D. Prime, and B. Sumby Latest advances in the development of dry powder inhalers Pharm. Sci. Technol. Today 3 2000 246 256
4. P. Brand, I. Friemel, T. Meyer, H. Schulz, J. Heyder, and K. Häußinger Total deposition of therapeutic particles during spontaneous and controlled inhalations J. Pharm. Sci. 89 2000 724 730
5. M.E.A.C. Broeders, J. Molema, and H.Th.M. Folgering Resistivities of placebo and active Diskus inhalers compared Int. J. Pharm. 228 2001 219 222
6. A.R. Clark, and A.M. Hollingworth The relationship between powder inhaler resistance and peak inspiratory conditions in healthy volunteers - implications for in vitro testing J. Aerosol Med. 6 1993 99 110
7. K. Corkery Inhalable drugs for systemic delivery Resp. Care 45 2000 831 835
8. N.R. Crowther Labiris, A.M. Holbrook, H. Chrystyn, S.M. Macleod, and M.T. Newhouse Dry powder versus intravenous and nebulized gentamicin in cystic fibrosis and bronchiectasis Am. J. Respir. Care Med. 160 1999 1711 1716
9. A.H. de Boer, P. Hagedoorn, D. Gjaltema, J. Goede, and H.W. Frijlink Air classifier technology (ACT) in dry powder inhalation. Part 1. Introduction of a novel force distribution concept (FDC) explaining the performance of a basic air classifier on adhesive mixtures Int. J. Pharm. 260 2003 187 200
10. A.H. de Boer, P. Hagedoorn, D. Gjaltema, J. Goede, K.D. Kussendrager, and H.W. Frijlink Air classifier technology (ACT) in dry powder inhalation. Part 2. The effect of lactose carrier surface properties on the drug-to-carrier interaction in adhesive mixtures for inhalation Int. J. Pharm. 260 2003 201 216
11. A.H. de Boer, P. Hagedoorn, D. Gjaltema, D. Lambregts, M. Irngartinger, and H.W. Frijlink The rate of drug particle detachment from carrier crystals in an air classifier-based inhaler Pharm. Res. 21 2004 2158 2166
12. A.H. de Boer, P. Hagedoorn, D. Gjaltema, D. Lambregts, M. Irngartinger, and H.W. Frijlink The mode of drug particle detachment from carrier crystals in an air classifier-based inhaler Pharm. Res. 21 2004 2167 2174
13. A.H. de Boer, P.P.H. Le Brun, H.G. van der Woude, P. Hagedoorn, H.G.M. Heijerman, and H.W. Frijlink Dry powder inhalation of antibiotics in cystic fibrosis therapy. Part 1. Development of a powder formulation with colistin sulphate for a special test inhaler with an air classifier as de-agglomeration principle Eur. J. Pharm. Biopharm. 54 2002 17 24
14. A.H. de Boer, H.M.I. Winter, and C.F. Lerk Inhalation characteristics and their effect on in vitro drug delivery from dry powder inhalers. Part 1. Inhalation characteristics, work of breathing and volunteers' preference in dependence of the inhaler resistance Int. J. Pharm. 130 1996 231 244
15. B.H.J. Dickhoff, A.H. de Boer, D. Lambregts, and H.W. Frijlink The effect of carrier surface and bulk properties on drug particle detachment from crystalline lactose carrier particles during inhalation, as function of carrier payload and mixing Eur. J. Pharm. Biopharm. 56 2003 291 302
16. B.H.J. Dickhoff, A.H. de Boer, D. Lambregts, and H.W. Frijlink The interaction between carrier rugosity and carrier payload, and its effect on drug particle redispersion from adhesive mixtures during inhalation Eur. J. Pharm. Biopharm. 59 2004 197 205
17. D.A. Edwards, A. Ben-Jebria, and R. Langer Recent advances in pulmonary drug delivery using large porous particles J. Appl. Physiol. 85 1998 379 385
18. M.-P. Flament, P. Leterme, and A. Gayot The influence of carrier roughness on adhesion, content uniformity and the in vitro deposition of terbutaline sulphate from dry powder inhalers Int. J. Pharm. 275 2004 201 209
19. T.R. Gerrity Pathophysiological and disease constraints on aerosol delivery P.R. Byron Respiratory Drug Delivery 1990 CRC Press Boca Raton 1 38
20. G.W. Hallworth, and U.G. Andrews Size analysis of suspension inhalation aerosols by inertial separation methods J. Pharm. Pharmacol. 28 1976 898 907
21. ® DPI Eur. J. Pharm. Sci. 16 2002 313 321
22. P.P.H. Le Brun, A.H. de Boer, G.P.M. Mannes, D.M.I. de Frâiture, R.W. Brimicombe, D.J. Touw, A.A. Vinks, H.W. Frijlink, and H.G.M. Heijerman Dry powder inhalation of antibiotics in cystic fibrosis therapy. Part 2. Inhalation of a novel colistin dry powder formulation: a feasibility study in healthy volunteers and patients Eur. J. Pharm. Biopharm. 54 2002 25 32
23. C. LiCalsi, T. Christensen, J.V. Bennett, E. Phillips, and C. Witham Dry powder inhalation as a potential delivery method for vaccines Vaccine 17 1999 1796 1803
24. M.D. Louey, S. Razia, and P.J. Stewart Influence of physico-chemical carrier properties on the in vitro aerosol deposition from interactive mixtures Int. J. Pharm. 252 2003 87 98
25. B.J. Meakin, D. Ganderton, I. Panza, and P. Ventura The effect of flow rate on drug delivery from the Pulvinal, a high resistance dry powder inhaler J. Aerosol Med. 11 1998 143 152
26. M.T. Newhouse, P.H. Hirst, S.P. Duddu, Y.H. Walter, T.E. Tarara, A.R. Clark, and J.G. Weers Inhalation of a dry powder tobramycin PulmoSphere formulation in healthy volunteers Chest 124 2003 360 366
27. S. Newman, S. Malik, P. Hirst, G. Pitcairn, A. Heide, J. Pabst, A. Dinkelaker, and W. Fleischer Lung deposition of salbutamol in healthy human subjects from the MAGhaler dry powder inhaler Resp. Med. 96 2002 1026 1032
28. M. Parry-Billings, R.N. Boyes, L.M. Clisby, P. Braithwate, S. Williams, and Harper Design, development and performance of a multi-dose dry powder inhaler Pharm. Technol. Eur. 2000 38 45
29. J.S. Patton Mechanisms of macromolecule absorption by the lungs Adv. Drug Del. Rev. 19 1996 3 36
30. J.S. Patton, J.G. Bukar, and M.A. Eldon Clinical pharmacokinetics and pharmacodynamics of inhaled insulin Clin. Pharmacokinet. 43 2004 781 801
31. R.H. Perry, and C.H. Chilton Chemical Engineers' Handbook 5th ed. 1973 McGraw-Hill Kogakusha Tokyo pp. 18-20 (Chapter 5)
32. P. Pohunek, M. Matulka, O. Rybnicek, F. Kopriva, H. Honomichlova, and T. Svobodova Dose-related efficacy and safety of formoterol (Oxis) Turbuhaler compared with salmeterol Diskhaler in children with asthma Pedriat. Allergy Immunol. 15 2004 32 39
33. H. Schiavone, S. Palakodaty, A. Clark, P. York, and S.T. Tzannis Evaluation of SCF-engineered particle-based lactose blends in passive dry powder inhalers Int. J. Pharm. 281 2004 55 66
34. ®, a novel multi-dose powder inhaler - comparison with metered dose inhaler Drug Today 32 1996 353 363
35. Skyepharma, 2001. Internet site: http://www.skyepharma.com/pdf/ webDPI0901.pdf.
36. J.N. Staniforth Order out of chaos J. Pharm. Pharmacol. 39 1986 329 334
37. H. Steckel, and H.W. Müller In vitro evaluation of dry powder inhalers. I. Drug deposition of commonly used devices Int. J. Pharm. 154 1997 19 29
38. ® particle engineering-technology development to pilot scale and commercial viability Proceedings on Drug Delivery to the Lungs, vol. XII London 2001 50 53
39. A. Voss, and W.H. Finlay De-agglomeration of dry powder pharmaceutical aerosols Int. J. Pharm. 248 2002 39 50
40. Z. Wang, C.F. Lange, and W.H. Finlay Use of an impinging jet for dispersion of dry powder inhalation aerosols Int. J. Pharm. 275 2004 123 131
41. K. Wetterlin Turbuhaler: a new powder inhaler for administration of drugs to the airways Pharm. Res. 5 1988 506 508
42. T.T. Yang, S. Li, B. Wyka, and D. Kenyon Drug delivery performance of the mometasone furoate dry powder inhaler J. Aerosol Med. 4 2001 487 494
43. X.M. Zeng, D. O'Leary, M. Phelan, S. Jones, and J. Colledge Delivery of salbutamol and of budesonide from a novel multi-dose inhaler Airmax™ Resp. Med. 96 2002 404 411